Taysha Gene Therapies: The Resignation Of R.a. Session Ii As The Company S President And Chief Executive Officer And The Appointment Of Each Of Sean Nolan As Chief Executive Officer And Sukumar Nagendran, M.d. As President And Head Of Research And Development. Severance Arrangements For Mr. Session Had Not Been Determined As Of The Filing Of The Original
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameTaysha Gene Therapies Inc
-
Registration countryUSA
-
IndustryPharmaceutical Preparation and Biotechnology
-
М/S&P/F
*** /*** /***









